Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

NCT01396070 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin Lymphoma (NHL)
Cutaneous Lymphoma
Cutaneous T-cell Lymphoma (CTCL)
Mycosis Fungoides
Sezary Syndrome

Interventions

DRUG: Brentuximab vedotin

Sponsor

Youn Kim

Collaborators

[object Object]